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Abstract. Early cancer diagnosis remains one of the most actual problems of medicine, since it allows using the most 
effective methods of cancer treating. Unlike most diagnostic methods used in oncology, the methods of nuclear medicine 
allow assessing not so much the anatomic changes in the organ as the disturbance of metabolic processes in tumors and 
surrounding tissues. The authors describe the main radiopharmaceuticals used for diagnose and radiotherapy of malignant 
tumors.
Early cancer diagnosis remains one of the most urgent problems of medicine, since it allows using the most 
effective methods of cancer treating. Unlike most diagnostic methods used in oncology, the methods of nuclear 
medicine allow assessing not only the anatomic changes in the organ but also the disturbance of metabolic processes 
in tumors and surrounding tissues.
Benign neoplasms consist of well-differentiated cells, the structure and function of which is similar to normal 
tissues. The rate of their growth is relatively small, they do not germinate nearby tissues and do not give metastases. 
Life-threatening situations can occur only in those cases when the tumor compresses vital organs, main vessels, 
tracts and ducts or produces an excessive amount of hormones and other biologically active substances. Surgical 
removal of benign tumors usually provides a persistent recovery of the patient. Malignant tumors consist of 
undifferentiated cells that have an atypical structure and function. Cancer cells can be scattered in the body (for 
example, in leukemia) or limited to the cellular association of tumor tissue. Malignant neoplasms are characterized 
by rapid growth, and in the absence of adequate treatment they metastasize to remote areas of the body, which in 
turn become new centers of atypical tissue growth. In malignant cells disrupted synthesis of specialized proteins, 
and begins to produce biologically active substances, some of which stimulate neoangiogenesis, promote metastasis. 
Dissemination tumor occurs both in the lymphatic system and hematogenous route. Each localization of cancer is 
characterized by the typical location of metastases. For example, in colon cancer metastasis begins most often in 
liver, in breast cancer—in bone.
Radiopharmaceuticals used for the diagnosis and treatment of tumors can be divided into the following groups:
Radiopharmaceuticals that can accumulate in tissues surrounding the tumor
– in intact tissues;
– in tissues altered by the tumor.
Radiopharmaceuticals that can accumulate on the membranes of tumor cells
– for the “antigen-antibody” reaction;
– on the mechanism of cellular reception.
Radiopharmaceuticals that can accumulate in tumor cells
– specific;
– nonspecific.
Radiopharmaceuticals for sentinel lymph nodes detection
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RADIOPHARMACEUTICALS THAT CAN ACCUMULATE IN INTACT TISSUES 
SURROUNDING THE TUMOR
This group of radiopharmaceuticals selectively accumulates in one or another tissue of the body and makes it 
possible to detect the presence of a tumor as a region of reduced accumulation of the agent. For example, a 99mTc 
colloid accumulating in Kupffer cells of the liver normally gives a uniform image, whereas a primary liver tumor or 
areas of its metastatic lesion are characterized by the appearance of “accumulation defects” of the radioactive agent 
corresponding to the localization of the neoplasm. It is quite obvious that this technique does not have high 
specificity, since any volumetric liver damage, for example, a cyst, is visualized in a similar way.
Other typical radiopharmaceuticals of this group include 99mTc pertechnetate [1] and iodine isotopes (123I or 
131I), which have been used for many years to diagnose thyroid tumors. These radiopharmaceuticals, accumulating 
in thyroid tissue, allow diagnosing malignant neoplasms in it by the presence of defects in the accumulation of 
agents. A disadvantage of the technique is its low specificity, as gland cysts similarly visualized as areas of reduced 
accumulation of the radiopharmaceutical.
In recent years, studies with radiopharmaceuticals of this group lost their popularity, yielding to less costly 
ultrasonic methods.
RADIOPHARMACEUTICALS THAT CAN ACCUMULATE IN TISSUES 
ALTERED BY THE TUMOR
The use of radiopharmaceuticals of this group is based on the phenomenon of their increased accumulation in the 
tissue surrounding the tumor. For example, the tissue surrounding the bone tumor responds to its growth with 
increased osteoblastic activity. Phosphate complexes of 99mTc, accumulating in osteoblasts, allow visualization of 
bone metastases and primary bone tumors at the earliest stage of their development as “hot foci”. Unfortunately, this 
highly sensitive method does not have high specificity, since enhanced accumulation of these radiopharmaceuticals 
in bone tissue can also be observed in fractures, osteomyelitis and some other diseases. The diagnostic accuracy of 
radionuclide techniques is enhanced when performed in the SPECT mode, especially when metastases are detected 
in the spine. In addition, the specificity of detection of malignant bone formation increases with the combination of 
SPECT and CT techniques.
Accumulation of phosphate complexes in osteoblasts is used in nuclear medicine for palliative therapy of bone 
metastases. Sm-153-oxabifore and Re-186-phosphate complexes are used for these purposes. These radionuclides 
affect the areas of osteoblastic activity with the help of E-radiation, and their J-quanta (103 and 137 KeV, 
respectively) can be detected with a gamma camera, visualizing the distribution of radiopharmaceuticals in the body.
Strontium-89 is also very popular for the treatment of bone metastases. Being a biological analogue of calcium, 
this radionuclide accumulates both in normal bone tissue and in areas with increased osteoblastic activity. But the 
clearance of the radiopharmaceutical from the metastatic lesions is much slower than from intact tissue. Unlike 
186Re and 153Sm, Strontium-89 is a pure E-emitter and with the help of a gamma camera it is impossible to register 
the distribution of this radiopharmaceutical in the body [1].
The second mechanism providing the phenomenon of hyperfixation of radiopharmaceuticals of this group in 
tissue sites surrounding the neoplasm is active angiogenesis induced in perifocal areas by biologically active 
malignant tumor factors. In this situation, the tumor is detected on the basis of increased accumulation of 99mTc 
erythrocytes in the intensively blood-supplying tissue regions surrounding the malignant tumor.
Unfortunately, the sensitivity and specificity of these techniques for tumor diagnosing is low. At the same time, 
some radionuclide therapy techniques are based on the phenomenon of enhanced blood supply to tumors, which are 
successfully used in the treatment of liver metastases. For these purposes, the introduction of 131I-lipidol, as well as 
Y-90-labeled resins or glass microspheres into the hepatic artery is used.
RADIOPHARMACEUTICALS THAT CAN ACCUMULATE ON THE MEMBRANES 
OF TUMOR CELLS FOR THE “ANTIGEN-ANTIBODY” REACTION
The diagnostic application of radiopharmaceuticals of this group in oncology is based on the reaction of labeled 
monoclonal antibodies with antigens of cancer cell membranes. In the diagnosis, both whole IgG-type antibodies 
and their fragments (Fab-fragments of antibody) were used [3]. Advantage Fab is a higher oncospecificity. However, 
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faster Fab’s clearance from the blood, compared to large molecules of immunoglobulins, due to renal excretion can 
reduce the tumor/background ratio in a tumor with low blood flow.
One of the problems that arises during the synthesis of labeled antibodies is a decrease in immunospecificity 
during the formation of radiopharmaceuticals. One way to solve this problem is to obtain the “antibody-
radionuclide” complex in vivo. In this case, first, intravenously injected antibodies, coupled with a chelate. After the 
accumulation the complex in the tumor patient is administered a radionuclide, which is connected to the chelate 
allows visualizing the tumor. The main advantage of this method is the reduction of non-specific binding of 
antibodies in combination with obtaining a high ratio of radioactivity “tumor/background” [4].
RADIOPHARMACEUTICALS THAT CAN ACCUMULATE ON THE MEMBRANES 
OF TUMOR CELLS ON THE MECHANISM OF CELLULAR RECEPTION
The use of such radiopharmaceuticals for diagnosis is based on the property of their affinity for certain receptors 
of tumor cell membranes.
Currently, the most frequently used radiopharmaceuticals of this type are somatostatin analogues—octreotide, 
labeled with 111In and 99mTc.
Somatostatin is a tetradecapeptide secreted by the hypothalamus, which suppresses the release of neuro-
endocrine hormones (growth hormone, glucagon, insulin and gastrin). Somatostatin receptors, among which five 
subtypes are distinguished, are widely represented in normal tissues, but in many malignant tumors and in certain 
inflammatory diseases, the density of these receptors is significantly increased. This overexpression is observed in 
most neuroendocrine tumors, in lung cancer, and also in the peritumoral veins of some human tumors, which creates 
a basis for differentiating these tumors from other tissues by radionuclide diagnostics using radiopharmaceuticals 
selectively binding to somatostatin receptors.
These radiopharmaceuticals have been used to diagnose a number of neuroendocrine tumors (carcinoid, 
pheochromacytoma, paraganglioma, melanoma), lung cancer, neoplasms of the central nervous system and 
lymphomas. The sensitivity and specificity of such malignant tumors detection using 111In-osteotide exceeds 80% 
[5]. However, the diagnosis of liver cancer and spleen lesions with this radiopharmaceutical has low efficiency due 
to high level of non-specific accumulation of this indicator in the organs. 99mTc-octreotide is used primarily for the 
detection of lung cancer. The sensitivity of SPECT/CT of malignant solitary pulmonary tumors reaches 97% with a 
specificity of 73%.
In recent years, 123I and 99mTc labeled peptides have been found in oncological practice, which are also 
capable of binding to the membranes of tumor cells. Labeled vasoactive intestinal peptides are used to visualize 
malignant neoplasms of the gastrointestinal tract and pancreas; labeled D-melanocyte-stimulating hormone is used to 
diagnose melanoma; labeled insulin is used to diagnose hepatoma and labeled neuropeptides are used to detect small 
cell lung cancer.
RADIOPHARMACEUTICALS THAT CAN ACCUMULATE IN TUMOR CELLS
BY SPECIFIC MECHANISM
Radiopharmaceuticals of this group are included in the specific metabolism of tumors (iodine isotopes 123I and 
131I, 123I-methoyiod-benzyl guanidine (123I-MIBG), 131I-methoyiod-benzyl guanidine (131I-MIBG) pentavalent 
99mTc (V)–DMSA).
Iodine-131 has been successfully used for more than 60 years to diagnose follicular and papillary thyroid cancer 
and, especially, its metastases [6].
Differentiated thyroid tumors retain the ability to capture iodine and include it in the synthesis of thyroid 
hormones. Malignant tumor in such cases is visualized as a “hot” focus, resembling a nodular thyrotoxic goiter, and 
metastases are detected as areas of extrathyroid ectopic accumulation.
It should be borne in mind that there is the possibility to obtain false-positive results due to the nonspecific 
uptake of iodine in the tissue of the salivary glands, as well as its excretion into the intestine and bladder. Low-
differentiated forms of thyroid cancer appear on scintigrams as “accumulation defects”, since atypical cells of these 
tumors lose their ability to metabolize iodine.
In recent years 123I has been used instead of 131I to perform radiodiagnostic procedures, which has a number of 
advantages: the optimal energy spectrum (159 KeV) for registration and a short half-life that helps to reduce the 
radiation dose to the patient.
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In 1982, a group of scientists led by Professor Ann Arbor from the University of Michigan (USA) synthesized 
123I-MIBG, which through the norepinephrine absorption mechanism is converted into catecholamines adrenergic 
nerve endings and adrenal medulla cells, thereby allowing visualization of the adrenal glands. In subsequent years, 
the high efficiency of the use of this radiopharmaceutical for the diagnosis of neuroendocrine tumors was shown, 
especially—pheochromocytoma, neuroblastoma, carcinoid, medullary thyroid cancer and paragangliomas. It should 
be noted that 131I-MIBG was effective for radionuclide therapy of these diseases.
Another radiopharmaceutical, specifically accumulated in the cells of medullary thyroid cancer, is pentavalent 
99mTc (V)-DMSA. Scintigraphy with this agent is a highly specific technique for detecting this neoplasm, but the 
mechanism of accumulation of 99mTc (V)-DMSA in the tumor remains unexplored.
RADIOPHARMACEUTICALS THAT CAN ACCUMULATE IN TUMOR CELLS 
BY NONSPECIFIC MECHANISM
Gallium-67 citrate has been successfully used for many years as a radiopharmaceutical for the diagnosis of 
tumors. Recently, the mechanism of its accumulation in a tumor cell has been studied, determined by the fact that 
67Ga after intravenous injection forms a complex with blood transferrin, which, in turn, binds to the receptors of 
some tumor cells. 67Ga-transferrin enters the cell through invagination of the cell membrane and, forming a 
complex with lactoferrin, remains in it.
67Ga-citrate has well established itself as a radiopharmaceutical for radionuclide diagnostics of lymphomas and 
small cell lung cancer. The literature describes application examples of the radiopharmaceutical for the detection of 
other malignancies. At the same time, nonspecific accumulation of 67Ga-citrate in the liver and excretion into the 
gastrointestinal tract limit its use for the diagnosis of abdominal tumors. In addition, 67Ga-citrate accumulates in the 
areas of infection and inflammation, which reduces the specificity of the method. Scintigraphy with this 
radiopharmaceutical has been successfully used to dynamically monitor a verified malignant neoplasm in the 
dynamics of chemo- or radiotherapy.
The isotopes of thallium (201Tl and 199Tl), being a biological analogue of potassium, are captured by the cell 
with the help of a sodium-potassium ATP-dependent pump and are localized in the mitochondria [8, 9]. These 
radiopharmaceuticals accumulate mainly in tissues with intensive energy metabolism (including atypical cells) and 
are widely used for the diagnosis of tumors, including neoplasms of bronchial tubes, lymphomas, thyroid cancer, 
bones and brain. Like 67Ga citrate, thallium isotopes are successfully used for the dynamic evaluation of chemo- or 
radiotherapy [9].
The non-specific positron-radiopharmaceutical—18F-fluorodeoxyglucose (18F-FDG) allows detecting a wide 
variety of malignant neoplasms with high sensitivity. The accumulation of this indicator in the cell is directly 
proportional to the efficiency of the e protein glucose transporter functioning and correlates with the activity of 
hexokinase II, the enzyme that realizes the exchange of the hydroxyl group of glucose for the phosphate complex of 
ATP. The phosphorylated metabolite of 18F-FDG loses its ability to transport through the cell membrane and 
remains intracellular. Thus, the high ratio of the concentration of radiopharmaceuticals "tumor/background" is 
achieved due to the significantly higher activity of hexokinase II in malignant cells. In recent years, there have been 
reports of the possible use of glucose labeled with technetium-99m as potential radiopharmaceutical for cancer 
diagnosis [10, 11].
The use of another nonspecific radiopharmaceutical for PET 11C-methionine for the diagnosis of tumors is 
based on a high level of amino acid metabolism in actively proliferating cells of malignant tumors. This indicator is 
used in the detection of lymphomas, malignant tumors of the neck and head.
Technetium-99m complexes with methoxy-isobutyl-isonitrile and tetrofosmin are actively used in nuclear 
oncology, thanks to the ability of these radiopharmaceuticals to accumulate in the mitochondria of malignant cells. 
Most of these indicators are used to detect breast cancer, larynx, lung tumors, lymphomas and myeloma [12–14].
RADIOPHARMACEUTICALS FOR SENTINEL LYMPH NODES DETECTION
Lymphoscintigraphy plays an important role in the diagnosis of lymphatic system in patients with edema of 
lower extremities. The method allows evaluating the function of lymphatic capillaries, transport of isotope through 
collectors and its accumulation in regional lymph nodes. Besides, radionuclide techniques have proven themselves 
to identify the so-called “sentinel” lymph nodes (SLN)—first lymph nodes on the path of lymph drainage from a 
malignant tumor. These nodes, filtering afferent lymph, become a “trap” for cancer cells, and that is why SLN 
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biopsy (followed by histological examination) is an objective diagnostic criterion for the spread of malignant 
process. It is believed that if the SLN are not affected by metastatic disease, all other regional lymph nodes remain 
intact [15]. The world practice has considerable experience in relation to radionuclide visualization of “sentinel” 
lymph nodes at melanoma and breast cancer. At tumors in other locations (lungs, head, neck, cervix, gastrointestinal 
tract) the effectiveness of this method is studied in scientific research [16, 17]. Optimal radiopharmaceutical to 
identify SLN is colloid labeled with technetium-99m. Determining factor in selecting indicator is the size is 
radioactive particles. Thus, according to Schauer A.J. et al. [14], a colloid with the size of the particle less than 50 
nm can accumulate not only in SLN, but also in subsequent nodes. Particles bigger than 100 nm slowly migrate from 
injection site. Colloid with the size of the particle from 50 to 80 nm was considered optimal for detecting SLN. 
Currently, in the Russian Federation there are no registered radiopharmaceuticals for SLN imaging. In this regard, 
the Tomsk Cancer Research Institute and Tomsk Polytechnic University developed by the original
radiopharmaceutical based on labeled with technetium-99m aluminum oxide (99mTc-Al2O3). An experimental and 
clinical study of this radiopharmaceutical showed that the accumulation level of 99mTc-Al2O3 in sentinel lymph 
nodes is several times higher in comparison with import agents, and its practical application will facilitate 
intraoperative identification of SLN [18].
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